- Home
- EUDA vs OBIO Comparison
EUDA vs OBIO Comparison
Compare EUDA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- OBIO
- Stock Information
- Founded
- EUDA 2021
- OBIO 2017
- Country
- EUDA Singapore
- OBIO United States
- Employees
- EUDA N/A
- OBIO N/A
- Industry
- EUDA Blank Checks
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- EUDA Finance
- OBIO Health Care
- Exchange
- EUDA Nasdaq
- OBIO Nasdaq
- Market Cap
- EUDA 149.4M
- OBIO 156.6M
- IPO Year
- EUDA N/A
- OBIO N/A
- Fundamental
- Price
- EUDA $3.76
- OBIO $5.17
- Analyst Decision
- EUDA
- OBIO Strong Buy
- Analyst Count
- EUDA 0
- OBIO 5
- Target Price
- EUDA N/A
- OBIO $15.80
- AVG Volume (30 Days)
- EUDA 102.6K
- OBIO 182.8K
- Earning Date
- EUDA 01-01-0001
- OBIO 11-12-2024
- Dividend Yield
- EUDA N/A
- OBIO N/A
- EPS Growth
- EUDA N/A
- OBIO N/A
- EPS
- EUDA N/A
- OBIO N/A
- Revenue
- EUDA $3,811,496.00
- OBIO $2,647,000.00
- Revenue This Year
- EUDA $121.80
- OBIO $22.61
- Revenue Next Year
- EUDA $78.17
- OBIO $16.64
- P/E Ratio
- EUDA N/A
- OBIO N/A
- Revenue Growth
- EUDA N/A
- OBIO N/A
- 52 Week Low
- EUDA $1.20
- OBIO $3.96
- 52 Week High
- EUDA $6.30
- OBIO $9.65
- Technical
- Relative Strength Index (RSI)
- EUDA 40.49
- OBIO 48.86
- Support Level
- EUDA $3.55
- OBIO $5.00
- Resistance Level
- EUDA $3.93
- OBIO $5.70
- Average True Range (ATR)
- EUDA 0.34
- OBIO 0.57
- MACD
- EUDA -0.09
- OBIO 0.03
- Stochastic Oscillator
- EUDA 19.66
- OBIO 51.71
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.